Method for optimally delivering virus to a solid tumor mass

• US 20020061298A1
• Filed: 11/15/2001
• Published: 05/23/2002
• Est. Priority Date: 11/20/2000
• Status: Abandoned Application

• Current Assignee: Oncolytics Biotech Incorporated
• Original Assignee: Oncolytics Biotech Incorporated
• Inventors: Coffey, Matthew C., Thompson, Bradley G.
• Application Number:
  US09/987,687
• Publication Number:
  US 20020061298A1
• Time in Patent Office: Days
• US Class Current: 424/93.21
• CPC Class Codes: A61K 35/765 Reovirus; Rotavirus
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 2720/12232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Abstract

This invention relates to a method for optimally delivering virus to a solid tumor. Two approaches can be adopted to increase the number of tumor cells inside the solid tumor which are exposed to virus. The virus can be delivered to multiple sites inside the solid tumor, or the virus can be delivered to a single site in such a large volume that the delivered virus is capable of reaching more tumor cells in the solid tumor.

Claims

1. A method for delivering a virus to a solid tumor to reduce growth of the tumor, comprising administering an effective amount of virus to a subject bearing the tumor, wherein the virus is capable of selectively killing tumor cells, by a base administration selected from the group consisting of:

(a) delivering a composition comprising the virus to multiple sites inside the solid tumor; and

(b) delivering directly into the tumor a composition comprising the virus, wherein the volume of the composition is between about 10% to about 100% of the volume of the tumor.

2. The method of claim 1 wherein the virus is reovirus.

3. The method of claim 2 wherein the reovirus is a mammalian reovirus.

4. The method of claim 3 wherein the mammalian reovirus is a human reovirus.

5. The method of claim 4 wherein the human reovirus is a serotype 3 virus.

6. The method of claim 5 wherein the serotype 3 virus is a Dearing strain virus.

7. The method of claim 1 wherein the virus is selected from the group consisting of modified adenovirus, modified HSV, modified vaccinia virus, modified parapoxvirus orf virus, p53-expressing viruses, the ONYX-015 virus, the Delta24 virus, vesicular stomatitis virus, the herpes simplex virus 1 mutant which is defective in hrR3, Newcastle disease virus, encephalitis virus, herpes zoster virus, hepatitis virus, influenza virus, varicella virus, and measles virus.

8. The method of claim 1(a) wherein the virus is delivered to at least 3 sites inside the tumor mass.

9. The method of claim 1(a) wherein the virus is delivered to at least 5 sites inside the tumor mass.

10. The method of claim 1(a) wherein the virus is delivered to one site per about 0.25 cubic centimeter of the tumor.

11. The method of claim 1(b) wherein the volume of the composition is at least 30% of the volume of the tumor.

12. The method of claim 1(b) wherein the volume of the composition is at least 50% of the volume of the tumor.

13. The method of claim 1(a) wherein the total volume of the virus composition delivered is between about 10% to about 100% of the volume of the tumor.

14. The method of claim 1 further comprising at least one additional administration selected from the group consisting of:

(a) delivering a composition comprising the virus to multiple sites inside the solid tumor; and

(b) delivering directly into the tumor a composition comprising the virus, wherein the volume of the composition is between about 10% to about 100% of the volume of the tumor;

(c) delivering the virus by using a transdermal patch, a spray on the skin, or topical administration, wherein the tumor is a superficial tumor; and

(d) delivering the virus systemically.

15. The method of claim 14 wherein the at least one additional administration is conducted before or after the base administration.

16. The method of claim 14 wherein the at least one additional administration is concurrent with the base administration.

17. The method of claim 14 wherein the virus is reovirus.

18. The method of claim 17 wherein the reovirus is a mammalian reovirus.

19. The method of claim 18 wherein the mammalian reovirus is a human reovirus.

20. The method of claim 19 wherein the hum an reovirus is a serotype 3 virus.

21. The method of claim 20 wherein the serotype 3 virus is a Dearing strain virus.